BioCentury
ARTICLE | Financial News

Acadia planning $150 million follow-on

March 4, 2014 1:58 AM UTC

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) proposed late Monday to raise up to $150 million in a follow-on underwritten by Jefferies; JPMorgan; and Cowen. Near the end of this year, Acadia plans to submit an NDA to FDA for pimavanserin to treat Parkinson's disease psychosis. The product is a small molecule serotonin (5-HT2A) receptor inverse agonist. ...